Immune-Onc Therapeutics



Description: 

Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.

Location(s): 
Palo Alto CA
United States